var data={"title":"Basiliximab: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Basiliximab: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5703?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=basiliximab-patient-drug-information\" class=\"drug drug_patient\">see &quot;Basiliximab: Patient drug information&quot;</a> and <a href=\"topic.htm?path=basiliximab-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Basiliximab: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5708643\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Experienced physician: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Only physicians experienced in immunosuppression therapy and management of organ transplantation patients should prescribe basiliximab. The physician responsible for basiliximab administration should have complete information requisite for the follow-up of the patient. Patients receiving the drug should be managed in facilities equipped with adequate laboratory and supportive medical resources.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F139095\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Simulect</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F139096\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Simulect</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F139126\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Immunosuppressant Agent;</li>\n      <li>\n        Monoclonal Antibody</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F139100\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Patients previously administered basiliximab should only be re-exposed to a subsequent course of therapy with extreme caution.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Renal transplant (prophylaxis of acute rejection):</b> IV: 20 mg within 2 hours prior to transplant surgery, followed by a second 20 mg dose 4 days after transplantation (in combination with other immunosuppressants). The second dose should be withheld if complications occur (including severe hypersensitivity reactions or graft loss). Timing of basiliximab dosing may vary based on clinical and institutional factors; refer to institutional protocol for specific information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Acute graft-versus-host disease (aGVHD), refractory (treatment) (off-label use):</b> IV: 20 mg on days 1 and 4; may repeat for recurrent acute GVHD (Schmidt-Hieber 2005). Additional data may be necessary to further define the role of basiliximab in this condition.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Heart transplant (prophylaxis of acute rejection) (off-label use):</b> IV: 20 mg on the day of transplant, followed by a second 20 mg dose on day 4 post-transplantation (in combination with other immunosuppressants) (Mehra 2005). The first dose is usually administered immediately prior to transplant or within the first hours postoperatively.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Liver transplant (prophylaxis of acute rejection) (off-label use): </b>IV: 20 mg on the day of transplant (day 0), followed by a second 20 mg dose on day 4 post-transplantation (in combination with other immunosuppressants) (Neuhaus 2002; Trunecka 2015). In clinical trials, the first dose was administered during the procedure once hemostasis was achieved or immediately post-transplant, or within 6 hours of organ reperfusion.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Lung transplant (prophylaxis of acute rejection) (off-label use</b>): IV: 20 mg prior to transplantation, followed by a second 20 mg dose 4 days after transplantation (in combination with other immunosuppressants) (Clinckart 2009; Swarup 2011). Additional trials may be necessary to further define the role of basiliximab in this condition.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F139116\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=basiliximab-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Basiliximab: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Patients previously administered basiliximab should only be re-exposed to a subsequent course of therapy with extreme caution.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Renal transplant (prophylaxis of acute rejection):</b> IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Children &lt;35 kg:</i> 10 mg within 2 hours prior to transplant surgery, followed by a second 10 mg dose 4 days after transplantation; the second dose should be withheld if complications occur (including severe hypersensitivity reactions or graft loss). Timing of basiliximab dosing may vary based on clinical and institutional factors; refer to institutional protocol for specific information.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Children and Adolescents &ge;35 kg:</i> Refer to adult dosing</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F139101\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15673269\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15673270\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F139077\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intravenous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Simulect: 10 mg (1 ea); 20 mg (1 ea)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F139062\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F139079\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">IV: For intravenous administration only. Infuse as a bolus or IV infusion over 20 to 30 minutes (bolus dosing is associated with nausea, vomiting, and local pain at the injection site); may be administered through either a peripheral or central line. For the treatment of acute GVHD (off-label use), the dose was administered over 30 minutes (Schmidt-Hieber 2005).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F139078\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Renal transplant (prophylaxis of acute rejection):</b> Prophylaxis of acute organ rejection in renal transplantation in combination with cyclosporine (modified) and corticosteroids</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">\n      <i>Guideline recommendations</i>: While basiliximab is FDA-approved for prophylaxis of acute organ rejection in renal transplantation in combination with cyclosporine (modified) and corticosteroids, cyclosporine is no longer recommended as the first line agent of choice. The Kidney Disease: Improving Global Outcomes (KDIGO) clinical practice guidelines for care of kidney transplant recipients recommend induction as part of the initial immunosuppressive regimen for all kidney transplants to reduce the risk of acute rejection. KDIGO recommends an interleukin 2 receptor antagonist (eg,basiliximab) as the first line induction agent for acute rejection prophylaxis except in those patients at high immunologic risk. (KDIGO [Kasiske 2009]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25721950\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Acute graft-versus-host disease, refractory (treatment); Heart transplant (prophylaxis of acute rejection); Liver transplant (prophylaxis of acute rejection); Lung transplant (prophylaxis of acute rejection)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25707942\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-4em;margin-left:6em;\">Basiliximab may be confused with bezlotoxumab.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes that have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F139069\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Frequency not defined. Administration of basiliximab did not appear to increase the incidence or severity of adverse effects in clinical trials. Adverse events were reported in 96% of both the placebo and basiliximab groups.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">&gt;10%: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cardiovascular: Hypertension, peripheral edema</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Central nervous system: Headache, insomnia, pain  </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Dermatologic: Acne vulgaris</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Endocrine &amp; metabolic: Hypercholesterolemia, hyperglycemia, hyperkalemia, hyperuricemia, hypokalemia, hypophosphatemia</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Gastrointestinal: Abdominal pain, constipation, diarrhea, dyspepsia, nausea, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Genitourinary: Urinary tract infection</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hematologic &amp; oncologic: Anemia </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Infection: Viral infection</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Neuromuscular &amp; skeletal: Tremor </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Respiratory: Dyspnea, upper respiratory infection</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Miscellaneous: Fever, postoperative wound complication</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">3% to 10%: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cardiovascular: Abnormal heart sounds, angina pectoris, atrial fibrillation, cardiac arrhythmia, cardiac failure, chest pain, hypotension, tachycardia, thrombosis</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Central nervous system: Agitation, anxiety, depression, dizziness, fatigue, hypoesthesia, malaise, rigors</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Dermatologic: Dermal ulcer, dermatological disease, hypertrichosis, pruritus, skin rash</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Endocrine &amp; metabolic: Acidosis, albuminuria, anasarca, dehydration, diabetes mellitus, hypercalcemia, hyperlipidemia, hypertriglyceridemia, hypervolemia, hypocalcemia, hypoglycemia, hypomagnesemia, hyponatremia, increased nonprotein nitrogen, increased serum glucocorticoids, weight gain </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Gastrointestinal: Enlargement of abdomen, esophagitis, flatulence, gastroenteritis, gastrointestinal hemorrhage, GI moniliasis, gingival hyperplasia, hernia, melena, stomatitis (including ulcerative)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Genitourinary: Bladder dysfunction, dysuria, genital edema (male), hematuria, impotence, oliguria, ureteral disease, urinary frequency, urinary retention</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hematologic &amp; oncologic: Hematoma, hemorrhage, hypoproteinemia, leukopenia, polycythemia, purpura, thrombocytopenia</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Infection: Cytomegalovirus disease, herpes virus infection (simplex and zoster), infection, sepsis</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Neuromuscular &amp; skeletal: Arthralgia, arthropathy, back pain, bone fracture, leg pain, muscle cramps, myalgia, neuropathy, paresthesia, weakness </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Ophthalmic: Cataract, conjunctivitis, visual disturbance</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Renal: Renal insufficiency, renal tubular necrosis</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Respiratory: Bronchitis, bronchospasm, cough, pharyngitis, pneumonia, pulmonary edema, rhinitis, sinusitis </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Miscellaneous: Accidental injury, cyst</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">&lt;1%, postmarketing, and/or case reports: Anaphylaxis, capillary leak syndrome, cytokine release syndrome, diabetes (new onset), hypersensitivity reaction (includes bronchospasm, cardiac failure, dyspnea, hypotension, pruritus, pulmonary edema, respiratory failure, skin rash, sneezing, tachycardia, urticaria), impaired glucose tolerance, increase in fasting plasma glucose, lymphoproliferative disorder</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F139082\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Known hypersensitivity to basiliximab or any component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F139066\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Anaphylactoid/hypersensitivity reactions: Severe hypersensitivity reactions, occurring within 24 hours, have been reported. Reactions, including anaphylaxis, have occurred both with the initial exposure and/or following re-exposure after several months; use caution during re-exposure to a subsequent course of therapy in a patient who has previously received basiliximab. Patients in whom concomitant immunosuppression was prematurely discontinued due to abandoned transplantation or early graft loss are at increased risk for developing a severe hypersensitivity reaction upon re-exposure. Discontinue permanently if a severe reaction occurs. Medications for the treatment of hypersensitivity reactions should be available for immediate use.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Diabetes: In renal transplant patients receiving basiliximab plus prednisone, cyclosporine, and mycophenolate, new-onset diabetes, glucose intolerance, and impaired fasting glucose were observed at rates significantly higher than observed in patients receiving prednisone, cyclosporine, and mycophenolate without basiliximab (Aasebo 2010).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Human antimurine antibodies (HAMA): Treatment may result in the development of HAMA; however, limited evidence suggesting the use of muromonab-CD3 or other murine products is not precluded.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Lymphoproliferative disorders: The incidence of lymphoproliferative disorders may be increased by immunosuppressive therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Opportunistic infections: The incidence of opportunistic infections may be increased by immunosuppressive therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: To be used as a component of an immunosuppressive regimen which includes cyclosporine and corticosteroids.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Experienced physician: <b>[US Boxed Warning]: Should be administered under the supervision of a physician experienced in immunosuppression therapy and organ transplant management.</b></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13298813\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F139071\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=8803&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Immunosuppressants may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Belimumab: Monoclonal Antibodies may enhance the adverse/toxic effect of Belimumab. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Coccidioides immitis Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioides immitis Skin Test. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Echinacea: May diminish the therapeutic effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fingolimod: Immunosuppressants may enhance the immunosuppressive effect of Fingolimod.  Management: Avoid the concomitant use of fingolimod and other immunosuppressants when possible. If combined, monitor patients closely for additive immunosuppressant effects (eg, infections).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nivolumab: Immunosuppressants may diminish the therapeutic effect of Nivolumab. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ocrelizumab: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pidotimod: Immunosuppressants may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tertomotide: Immunosuppressants may diminish the therapeutic effect of Tertomotide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or nonbiologic disease modifying antirheumatic drugs (DMARDs) is permitted, and this warning seems particularly focused on more potent immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).  Management: Vaccine efficacy may be reduced. Complete all age-appropriate vaccinations at least 2 weeks prior to starting an immunosuppressant. If vaccinated during immunosuppressant therapy, revaccinate at least 3 months after immunosuppressant discontinuation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.<i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F139073\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">B (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F139083\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;\">Adverse effects were not observed in animal reproduction studies. Basiliximab is a monoclonal IgG antibody which targets IL-2 receptors. IgG is known to cross the placenta; IL-2 receptors play an important role in the development of the immune system.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Women of childbearing potential should use effective contraceptive measures before beginning treatment, during, and for 4 months after completion of basiliximab treatment.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">The National Transplantation Pregnancy Registry (NTPR) is a registry which follows pregnancies which occur in maternal transplant recipients or those fathered by male transplant recipients. The NTPR encourages reporting of pregnancies following solid organ transplant by contacting them at 877-955-6877 or NTPR@giftoflifeinstitute.org.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F139084\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if basiliximab is present in human milk. Because many immunoglobulins are secreted in milk and the potential for serious adverse reactions exists, a decision should be made to discontinue breastfeeding or discontinue the drug, taking into account the importance of the drug to the mother.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F139075\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Monitor for signs and symptoms of acute rejection; hypersensitivity, infection</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F139065\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Basiliximab is a chimeric (murine/human) immunosuppressant monoclonal antibody which blocks the alpha-chain of the interleukin-2 (IL-2) receptor complex; this receptor is expressed on activated T lymphocytes and is a critical pathway for activating cell-mediated allograft rejection</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F139081\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Duration: Mean: 36 days &plusmn; 14 days  (determined by IL-2R alpha saturation in patients also on cyclosporine and corticosteroids)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: Mean: V<sub>d</sub>: Children 1 to 11 years: 4.8 &plusmn; 2.1 L; Adolescents 12 to 16 years: 7.8 &plusmn; 5.1 L; Adults: 8.6 &plusmn; 4.1 L</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: Children 1 to 11 years: 9.5 &plusmn; 4.5 days; Adolescents 12 to 16 years: 9.1 &plusmn; 3.9 days; Adults: Mean: 7.2 &plusmn; 3.2 days</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Clearance: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\"> Children 1 to 11 years: 17 &plusmn; 6 mL/hour; in pediatric liver transplant patients, significant basiliximab loss through ascites fluid can increase total body clearance and reduce IL-2R (CD25) saturation duration; dosage adjustments may be necessary (Cintorino 2006; Kovarik 2002; Spada 2006)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adolescents 12 to 16 years: 31 &plusmn;19 mL/hour</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adults: 41 &plusmn; 19 mL/hour</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323008\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Simulect Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (1): $3,277.10</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg (1): $4,301.22</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F139085\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Simulect (AE, AR, AT, AU, BB, BE, BG, BH, BR, CH, CL, CN, CO, CY, CZ, DE, DK, EC, EE, ES, FI, FR, GB, GR, HK, HN, HR, HU, ID, IE, IL, IN, IS, IT, JP, KR, KW, LB, LK, LT, LV, MT, MX, MY, NL, NO, NZ, PE, PH, PK, PL, PT, PY, QA, RO, RU, SA, SE, SG, SI, SK, TH, TR, TW, UY, VE, VN);</li>\n      <li>Simulekt (UA)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Aaseb&oslash; W, Midtvedt K, Valderhaug TG, et al, &ldquo;Impaired Glucose Homeostasis in Renal Transplant Recipients Receiving Basiliximab,&rdquo; <i>Nephrol Dial Transplant</i>, 2010, 25(4):1289-93.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/basiliximab-drug-information/abstract-text/19934089/pubmed\" target=\"_blank\" id=\"19934089\">19934089</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Brennen DC, Daller JA, Lake KD, et al, &ldquo;Rabbit Antithymocyte Globulin Versus Basiliximab in Renal Transplantation,&rdquo; <i>N Engl J Med</i>, 2006, 355(19):1967-77.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/basiliximab-drug-information/abstract-text/17093248/pubmed\" target=\"_blank\" id=\"17093248\">17093248</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cintorino D, Riva S, Spada M, et al, &quot;Corticosteroid-Free Immunosuppression in Pediatric Liver Transplantation: Safety and Efficacy After a Short-Term Follow-Up,&quot; <i>Transplant Proc</i>, 2006, 38(4):1099-100.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/basiliximab-drug-information/abstract-text/16757276/pubmed\" target=\"_blank\" id=\"16757276\">16757276</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"19328937\"></a>Clinckart F, Bulpa P, Jamart J, et al. Basiliximab as an alternative to antithymocyte globulin for early immunosuppression in lung transplantation. <i>Transplant Proc</i>. 2009;41(2):607-609.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/basiliximab-drug-information/abstract-text/19328937/pubmed\" target=\"_blank\" id=\"19328937\">19328937</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"26833657\"></a>Furuya Y, Jayarajian SN, Taghavi S, et al. The impact of alemtuzumab and basiliximab induction on patient survival and time to bronchiolitis obliterans syndrome in double lung transplantation recipients. <i>Am J Transplant</i>. 2016;16(8):2334-2341.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/basiliximab-drug-information/abstract-text/26833657/pubmed\" target=\"_blank\" id=\"26833657\">26833657</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kahan BD, Rajagopalan PR, and Hall M, &ldquo;Reduction of the Occurrence of Acute Cellular Rejection Among Renal Allograft Recipients Treated With Basiliximab, a Chimeric Anti-Interleukin-2-Receptor Monoclonal Antibody. United States Simulect Renal Study Group,&rdquo; <i>Transplantation</i>, 1999, 67(2):276-84.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/basiliximab-drug-information/abstract-text/10075594/pubmed\" target=\"_blank\" id=\"10075594\">10075594</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"19845597\"></a>Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients. <i>Am J Transplant</i>. 2009;9 Suppl 3:S1-155.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/basiliximab-drug-information/abstract-text/19845597/pubmed\" target=\"_blank\" id=\"19845597\">19845597</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kovarik JM, Gridelli BG, Martin S, et al, &quot;Basiliximab in Pediatric Liver Transplantation: A Pharmacokinetic-Derived Dosing Algorithm,&quot; <i>Pediatr Transplant</i>, 2002, 6(3):224-30.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/basiliximab-drug-information/abstract-text/12100507/pubmed\" target=\"_blank\" id=\"12100507\">12100507</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"16143248\"></a>Mehra MR, Zucker MJ, Wagoner L, et al, &ldquo;A Multicenter, Prospective, Randomized, Double-Blind Trial of Basiliximab in Heart Transplantation,&rdquo; <i>J Heart Lung Transplant</i>, 2005, 24(9):1297-304.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/basiliximab-drug-information/abstract-text/16143248/pubmed\" target=\"_blank\" id=\"16143248\">16143248</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nashan B, Moore R, Amlot P, et al, &ldquo;Randomised Trial of Basiliximab Versus Placebo for Control of Acute Cellular Rejection in Renal Allograft Recipients,&rdquo; <i>Lancet</i>, 1997, 350(9086):1193-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/basiliximab-drug-information/abstract-text/9652559/pubmed\" target=\"_blank\" id=\"9652559\">9652559</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"11862589\"></a>Neuhaus P, Clavien PA, Kittur D, et al, &ldquo;Improved Treatment Response With Basiliximab Immunoprophylaxis After Transplantation: Results From a Double-Blind Randomized Placebo-Controlled Trial,&rdquo; <i>Liver Transpl</i>, 2002, 8(2):132-42.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/basiliximab-drug-information/abstract-text/11862589/pubmed\" target=\"_blank\" id=\"11862589\">11862589</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Offner G, Toenshoff B, H&ouml;cker B, et al, &ldquo;Efficacy and Safety of Basiliximab in Pediatric Renal Transplant Patients Receiving Cyclosporine, Mycophenolate Mofetil, and Steroids,&rdquo; <i>Transplantation</i>, 2008, 86(9):1241-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/basiliximab-drug-information/abstract-text/19005406/pubmed\" target=\"_blank\" id=\"19005406\">19005406</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"16098072\"></a>Schmidt-Hieber M, Feitz T, Knauf W, et al, &ldquo;Efficacy if the Interleukin-2 Receptor Antagonist Basiliximab in Steroid-Refractory Acute Graft-Versus-Host Disease, <i>Br J Haematol</i>, 2005, 130(4):568-74.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/basiliximab-drug-information/abstract-text/16098072/pubmed\" target=\"_blank\" id=\"16098072\">16098072</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Simulect (basiliximab) (prescribing information). East Hanover, NJ: Novartis Pharmaceuticals Corporation; October, 2009.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Simulect (basiliximab) [product monograph]. Dorval, Quebec, Canada: Novartis Pharmaceuticals Canada Inc; July 1014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Spada M, Petz W, Bertani A, et al, &quot;Randomized Trial of Basiliximab Induction Versus Steroid Therapy in Pediatric Liver Allograft Recipients Under Tacrolimus Immunosuppression,&quot; <i>Am J Transplant</i>, 2006, 6(8):1913-1921.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"21764603\"></a>Swarup R, Allenspach LL, Nemeh HW, et al. Timing of basiliximab induction and development of acute rejection in lung transplant patients. <i>J Heart Lung Transplant</i>. 2011;30(11):1228-1235.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/basiliximab-drug-information/abstract-text/21764603/pubmed\" target=\"_blank\" id=\"21764603\">21764603</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"25707487\"></a>Trunecka P, Klempnauer J, Bechstein WO, et al. Renal function in de novo liver transplant recipients receiving different prolonged-release tacrolimus regimens &ndash; the DIAMOND study. <i>Am J Transplant</i>. 2015;15(7):1843-1854.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/basiliximab-drug-information/abstract-text/25707487/pubmed\" target=\"_blank\" id=\"25707487\">25707487</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"14742976\"></a>Webster AC, Playford EG, Higgins G, Chapman JR, Craig JC. Interleukin 2 receptor antagonists for renal transplant recipients: a meta-analysis of randomized trials. <i>Transplantation</i>. 2004;77(2):166-176.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/basiliximab-drug-information/abstract-text/14742976/pubmed\" target=\"_blank\" id=\"14742976\">14742976</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"27813419\"></a>Zhang Y, Jin W, Cai X. Anti-interleukin-2 receptor antibodies for the prevention of rejection in liver transplant recipients: a systematic review and meta-analysis. <i>Ann Med</i>. 2016;1-33.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/basiliximab-drug-information/abstract-text/27813419/pubmed\" target=\"_blank\" id=\"27813419\">27813419</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 8803 Version 129.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5708643\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F139095\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F139096\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F139126\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F139100\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F139116\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F139101\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F15673269\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F15673270\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F139077\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F139062\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F139079\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F139078\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25721950\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F25707942\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F139069\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F139082\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F139066\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13298813\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F139071\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F139073\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F139083\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F139084\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F139075\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F139065\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F139081\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323008\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F139085\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/8803|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=basiliximab-patient-drug-information\" class=\"drug drug_patient\">Basiliximab: Patient drug information</a></li><li><a href=\"topic.htm?path=basiliximab-pediatric-drug-information\" class=\"drug drug_pediatric\">Basiliximab: Pediatric drug information</a></li></ul></div></div>","javascript":null}